Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19534281 | 0.88 | GPR119 (0.51) | GPR119TACR1POLBCYP3A4CYP2C19 | |
| SCHEMBL31537258 | 0.88 | POLB (0.56) | GPR119TACR1POLBALDH1A1CYP2C19 | |
| SCHEMBL21151156 | 0.87 | GPR119 (0.56) | ARGPR119GRM1POLBCYP3A4 | |
| SCHEMBL30327653 | 0.86 | TACR1 (0.56) | ARGPR119TACR1POLBCYP2C19 | |
| SCHEMBL21151418 | 0.86 | TACR1 (0.45) | GPR119TACR1POLBALDH1A1CYP2C19 | |
| SCHEMBL30694554 | 0.86 | TACR1 (0.45) | GPR119TACR1POLBALDH1A1CYP2C19 | |
| SCHEMBL30328160 | 0.83 | AR (0.56) | ARGPR119TACR1POLBUSP30 | |
| SCHEMBL23288924 | 0.83 | TACR1 (0.43) | GPR119TACR1POLBALDH1A1CYP2C19 | |
| SCHEMBL21151347 | 0.83 | GPR119 (0.48) | ARGPR119TACR1POLBALDH1A1 | |
| SCHEMBL21151784 | 0.83 | HRH3 (0.51) | GPR119TACR1POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | AR 1357/4885HIF1A 1669/4885GPR119 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.